Adaptive Research Launches Decentralized Clinical Trial in Parkinson’s Disease

SAN FRANCISCO, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Adaptive Research, a clinical trial site organization dedicated to democratizing clinical trials, announced its participation in a groundbreaking decentralized study for Parkinsons’ Disease sponsored by PhotoPharmics Inc. California Movement Disorders Center, part of Adaptive Research’s network, will serve as a site for PhotoPharmics’ LIGHT-PD trial, testing the efficacy of Celeste® Specialized Phototherapy in treating Parkinson’s symptoms.Key Highlights:Decentralized trial design allows for remote monitoring through telehealth visitsDr. Kristin Andruska from Adaptive Research network to serve as investigatorStudy showcases the potential for community physicians to participate in advanced clinical trials "The decentralized approach of the LIGHT-PD trial is revolutionizing Parkinson's research," said study investigator Kristin Andruska, MD, PhD. "Using remote, home-based assessments, Adaptive Research can now include participants from a wide geography. This not only provides a more diverse patient population but also makes the trial accessible to those who might otherwise be unable to participate. It's an exciting step towards more inclusive clinical research."Deepak Behera, MD, CEO of Adaptive Research, added, "The at-home, telemedicine-based design of this trial aligns perfectly with Adaptive Research's vision for the future of clinical studies. It exemplifies our commitment to enhancing accessibility and convenience, enabling broader participation across diverse populations and geographies. Moreover, this study showcases how community physicians, when provided with the right support, can effectively contribute to cutting-edge, decentralized clinical trials."“LIGHT-PD will be the largest phototherapy trial of its kind and holds immense promise for those affected by Parkinson’s Disease and has received FDA Breakthrough Designation for its potential in improving PD symptoms. We welcome the California Movement Disorders Center and Adaptive Research to the ranks of movement disorder neurologists across the country who are enrolling and caring for trial participants,” said Dan Adams, CSO, PhotoPharmics, Inc.About the LIGHT-PD TrialThe LIGHT-PD trial (Double-blind, Randomized Controlled Trial to Demonstrate…

Continue Reading

End of content

No more pages to load

Close Navigation